Articles

Filing: Roche considered leaving Indy

It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.

Read More

Q&A

Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.

Read More

Fieldhouse gets Bankers Life name

It will be difficult to rebrand the arena where the Indiana Pacers play, but team officials praised sponsor CNO Financial for sticking with the $20 million naming-rights deal despite tough times.

Read More

Lilly enters drug-development deal with Immunogen

Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.

Read More

Hoosiers like parts of health reform law

As it is in the rest of the country, the 2010 health reform in Indiana continues to be unpopular, unlikely to be repealed and uncertain to put a dent in health spending, according to a poll of Hoosiers released last week by Ball State University.

Read More

Independent doctors fear loss of referrals

Independent health care facilities, like Body One Physical Therapy, are seeing referrals from physicians beginning to slacken as more and more doctors become employees of hospitals. The hospitals request that doctors send patients to their in-house physical therapy practices.

Read More

Endocyte shares plunge on clinical trial results

Shares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.

Read More